Novartis CEO plans gene therapy price 'far lower' than $4 mln to $5 mln range

诺华公司CEO计划脊髓型肌萎缩的基因治疗价格将控制在150万至500万美元之间

2019-05-23 11:32:00 YAHOO!FINANCE

本文共654个字,阅读需2分钟

By Caroline Humer BOSTON, May 22 (Reuters) - Novartis AG's top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drugmaker has said it could be worth. U.S. regulators are expected to make a decision this month on whether to approve Zolgensma, a one-time therapy seen as a potential long-term solution for the rare disease that is the leading genetic cause of death in infants. The company has previously said it could price the treatment in a range of $1.5 million to $5 million. “We won’t be announcing the price until we get the approval. But our overall goal is to be at a fraction of what is the current standard of care, and the current standard of care for treating these patients is $4 million to $5 million over 10 years,” Novartis Chief Executive Vas Narasimhan told reporters on Wednesday in Boston. The current treatment for SMA, which can lead to paralysis, breathing difficulty and early death, is Biogen Inc's Spinraza. That drug has a list price of $750,000 for the initial year and $375,000 annually thereafter. Narasimhan said his company's ultra-rare disease therapy would be cost effective in a range of $4.6 million to $5.4 million. “We want to be far lower than that,” he said. Novartis is expecting the drug initially to be approved for infants and is in discussions with the U.S. Food and Drug Administration about whether approval will include other forms of the disease beyond the most serious Type 1, he said. The company is also in late stage discussions with commercial insurers over the price of the treatment. (Reporting by Caroline Humer Editing by Bill Berkrot)
卡罗琳·休默 路透波士顿5月22日电---诺华公司( Novartis AG )首席执行官周三表示,预计其脊肌萎缩症基因治疗价格将“远低于”瑞士制药商所称的400万至500万美元的价格. 美国监管机构预计本月将就是否批准 Zolgensma 做出决定。 Zolgensma 是一种一次性治疗方法,被认为是一种潜在的长期治疗方法,用于治疗婴儿死亡的主要基因病因罕见疾病。该公司此前曾表示,可能会对治疗定价在150万至500万美元之间。 “只有获得批准,我们才会宣布价格。但诺华(Novartis)首席执行官 Vas Narasimhan 周三在波士顿对记者表示:“我们的总体目标是,在目前的护理标准基础上,在10年内,目前治疗这些患者的护理标准是400万至500万美元。” 目前治疗 SMA ,这可能导致瘫痪,呼吸困难和早期死亡,是百健(Biogen)公司的 Spiraza 。该药物最初一年的定价为75万美元,此后每年的标价为375000美元。 Narasimhan 说,他的公司的超罕见疾病疗法的成本效益将在460万到540万美元之间。“我们希望远低于这个水平,”他说。 他说,诺华(Novartis)公司预计该药物最初将被批准用于婴儿,目前正在与美国食品药品监督管理局(Food and Drug Administration)讨论是否批准将包括最严重的1型以外的其他形式的疾病。 该公司还在后期与商业保险公司就治疗价格进行讨论。( Caroline Humer 编辑 Bill Berkrot 的报告)

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文